TWST
Twist Bioscience Corp
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$139.77
+5.29%Year over year
Reported trailing growth
- Revenue
- +19.2%
- EBITDA
- -82.3%
- EBIT
- +3.2%
- EPS
- -53.1%
- Free cash flow
- -35.5%
- Operating cash flow
- -3.8%
Forward estimates
Based on analyst estimates
- Revenue
- +27.1%
- EBITDA
- +58.2%
- EPS
- +39.9%
Three-year CAGR
- Revenue
- +22.8%
- EBITDA
- +70.5%
- EBIT
- +38.3%
- Net income
- +62.8%
- EPS
- +63.9%
- Free cash flow
- -9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026